Abeona Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Abeona Therapeutics Inc. reports FDA approval for ZEVASKYN, generating significant revenue from a Priority Review Voucher sale, while continuing to advance its gene therapy pipeline.
NASDAQ
Abeona Therapeutics Inc. files its Form 10-K, detailing the company's financial results, business activities, and progress in developing cell and gene therapies for life-threatening diseases, with a focus on its lead program, pz-cel, for recessive dystrophic epidermolysis bullosa (RDEB).
NASDAQ
Abeona Therapeutics emphasizes its commitment to ethical business practices and compliance in its recent 10-K filing, outlining standards for all employees and stakeholders.